{
"id":"mk19_b_en_t10",
"number":10,
"bookId":"en",
"title":{
"__html":"Pharmacologic Agents Used to Lower Blood Glucose Levels in Type 2 Diabetes Mellitus<sup>a,b</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"770d29",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 10. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t10"
}
]
},
"Pharmacologic Agents Used to Lower Blood Glucose Levels in Type 2 Diabetes Mellitus",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a,b"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bd813",
"class":"col hd l",
"children":[
"Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6cdc4b",
"class":"col hd l",
"children":[
"Mechanism of Action"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"544914",
"class":"col hd l",
"children":[
"Effect on Weight"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90843c",
"class":"col hd l",
"children":[
"Disadvantages"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa9373",
"class":"col hd l",
"children":[
"Long-Term Studies on Definitive Outcomes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"38ef85",
"class":"cell txt l",
"children":[
"Insulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d222fb",
"class":"cell txt l",
"children":[
"Decreases hepatic glucose production"
]
},
" ",
{
"type":"p",
"hlId":"1dc9f5",
"class":"cell txt l",
"children":[
"Increases peripheral glucose uptake"
]
},
" ",
{
"type":"p",
"hlId":"937124",
"class":"cell txt l",
"children":[
"Suppresses ketogenesis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aac247",
"class":"cell txt l",
"children":[
"Increase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"428042",
"class":"cell txt l",
"children":[
"Hypoglycemia, training required, injectable forms, pulmonary toxicity with inhaled insulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cd9e2f",
"class":"cell txt l",
"children":[
"Decrease in microvascular events (UKPDS)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c,d"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca3a81",
"class":"cell txt l",
"children":[
"Sulfonylureas (tolbutamide, chlorpropamide, glipizide, glyburide, gliclazide, glimepiride)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f3abac",
"class":"cell txt l",
"children":[
"Stimulates insulin secretion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aac247",
"class":"cell txt l",
"children":[
"Increase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6e9a66",
"class":"cell txt l",
"children":[
"Hypoglycemia (especially in drugs with long half-lives or in older populations); lacks glucose-lowering durability"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca9296",
"class":"cell txt l",
"children":[
"Decrease in microvascular events (UKPDS)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"; possible increase in CVD events"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"19a17b",
"class":"cell txt l",
"children":[
"Biguanides (metformin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d222fb",
"class":"cell txt l",
"children":[
"Decreases hepatic glucose production"
]
},
" ",
{
"type":"p",
"hlId":"41aa18",
"class":"cell txt l",
"children":[
"Increases insulin-mediated uptake of glucose in muscles"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"70da5c",
"class":"cell txt l",
"children":[
"Diarrhea and abdominal discomfort, vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" deficiency, lactic acidosis (rare)"
]
},
" ",
{
"type":"p",
"hlId":"4de91f",
"class":"cell txt l",
"children":[
"Contraindicated with progressive liver, kidney, or cardiac failure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff1e35",
"class":"cell txt l",
"children":[
"Decrease in CVD events (UKPDS)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9552c2",
"class":"cell txt l",
"children":[
"α-Glucosidase inhibitors (acarbose, miglitol)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"190a99",
"class":"cell txt l",
"children":[
"Inhibits polysaccharide absorption"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"977cfd",
"class":"cell txt l",
"children":[
"Flatulence, abdominal discomfort"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bb8b8",
"class":"cell txt l",
"children":[
"Possible decrease in CVD events in prediabetes (STOP-NIDDM)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f09885",
"class":"cell txt l",
"children":[
"Thiazolidinediones (rosiglitazone, pioglitazone)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6884e",
"class":"cell txt l",
"children":[
"Increases peripheral uptake of glucose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aac247",
"class":"cell txt l",
"children":[
"Increase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d8dbbd",
"class":"cell txt l",
"children":[
"Fluid retention, heart failure, edema, fractures, possible increased risk of bladder cancer with pioglitazone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"082199",
"class":"cell txt l",
"children":[
"Possible decrease in CVD events with pioglitazone (PROactive)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"74a123",
"class":"cell txt l",
"children":[
"Meglitinides (repaglinide, nateglinide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ce90c",
"class":"cell txt l",
"children":[
"Stimulates insulin release"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aac247",
"class":"cell txt l",
"children":[
"Increase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c1870e",
"class":"cell txt l",
"children":[
"Hypoglycemia, frequent dosing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d6e4b4",
"class":"cell txt l",
"children":[
"Amylin mimetic (pramlintide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"455909",
"class":"cell txt l",
"children":[
"Slows gastric emptying"
]
},
" ",
{
"type":"p",
"hlId":"c4263f",
"class":"cell txt l",
"children":[
"Suppresses glucagon secretion"
]
},
" ",
{
"type":"p",
"hlId":"7386b0",
"class":"cell txt l",
"children":[
"Increases satiety"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e661c",
"class":"cell txt l",
"children":[
"Decrease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"db0b8c",
"class":"cell txt l",
"children":[
"Nausea, vomiting, exacerbation of gastroparesis, increased hypoglycemia risk with concomitant use of insulin, training required, injectable, frequent dosing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57241a",
"class":"cell txt l",
"children":[
"DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1629c",
"class":"cell txt l",
"children":[
"Glucose-dependent increase in insulin secretion"
]
},
" ",
{
"type":"p",
"hlId":"a61db1",
"class":"cell txt l",
"children":[
"Glucose-dependent suppression of glucagon secretion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"168ed1",
"class":"cell txt l",
"children":[
"Hypoglycemia when used in combination with sulfonylureas, increased risk of infections, possible increased risk of pancreatitis, dermatologic reactions, requires dose adjustments for decreasing kidney function except for linagliptin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"397f46",
"class":"cell txt l",
"children":[
"Increased heart failure hospitalizations (saxagliptin [SAVOR-TIMI 53])",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"g"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"275dac",
"class":"cell txt l",
"children":[
"GLP-1 receptor agonists (exenatide, exenatide extended release, liraglutide, lixisenatide, dulaglutide, semaglutide, oral semaglutide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1629c",
"class":"cell txt l",
"children":[
"Glucose-dependent increase in insulin secretion"
]
},
" ",
{
"type":"p",
"hlId":"455909",
"class":"cell txt l",
"children":[
"Slows gastric emptying"
]
},
" ",
{
"type":"p",
"hlId":"a61db1",
"class":"cell txt l",
"children":[
"Glucose-dependent suppression of glucagon secretion"
]
},
" ",
{
"type":"p",
"hlId":"7386b0",
"class":"cell txt l",
"children":[
"Increases satiety"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e661c",
"class":"cell txt l",
"children":[
"Decrease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a3577",
"class":"cell txt l",
"children":[
"Hypoglycemia when used in combination with sulfonylureas, nausea, vomiting, diarrhea, exacerbation of gastroparesis, increased heart rate, possible pancreatitis, C-cell hyperplasia and medullary thyroid tumors demonstrated in animal studies, training required, injectable (except oral semaglutide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ee6497",
"class":"cell txt l",
"children":[
"Decrease in CVD events and mortality in individuals at high risk with type 2 diabetes with liraglutide (LEADER)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"h"
]
}
]
},
" ",
{
"type":"p",
"hlId":"909e26",
"class":"cell txt l",
"children":[
"Decrease in new or worsening nephropathy in individuals at high risk with type 2 diabetes with liraglutide (LEADER)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"h"
]
}
]
},
" ",
{
"type":"p",
"hlId":"565be8",
"class":"cell txt l",
"children":[
"Decrease in nonfatal MI, nonfatal stroke, or CV death with semaglutide (SUSTAIN-6)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"i"
]
}
]
},
" ",
{
"type":"p",
"hlId":"24ef36",
"class":"cell txt l",
"children":[
"Decrease in new or worsening nephropathy in individuals at high risk with type 2 diabetes with semaglutide (SUSTAIN-6)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"i"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cba84c",
"class":"cell txt l",
"children":[
"SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"301a6a",
"class":"cell txt l",
"children":[
"Increases kidney excretion of glucose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e661c",
"class":"cell txt l",
"children":[
"Decrease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d10443",
"class":"cell txt l",
"children":[
"Hypoglycemia with insulin secretagogues, dehydration/hypotension, acute kidney injury (canagliflozin, dapagliflozin), hypersensitivity reactions, increased ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" infections, urinary tract infections, Fournier gangrene, “euglycemic” DKA, increase in lower limb amputations (canagliflozin), hyperkalemia (canagliflozin), fractures (canagliflozin), bladder cancer (dapagliflozin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"60f749",
"class":"cell txt l",
"children":[
"Decrease in CVD events and mortality in high-risk individuals with type 2 diabetes with empagliflozin (EMPA-REG OUTCOME)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"j"
]
}
]
},
" ",
{
"type":"p",
"hlId":"5dffb1",
"class":"cell txt l",
"children":[
"Decrease in incident or worsening nephropathy in individuals at high CVD risk with type 2 diabetes (EMPA-REG OUTCOME)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"j"
]
}
]
},
" ",
{
"type":"p",
"hlId":"e1d88f",
"class":"cell txt l",
"children":[
"Decrease in CVD events in high-risk individuals with type 2 diabetes with canagliflozin (CANVAS Program)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"k"
]
}
]
},
" ",
{
"type":"p",
"hlId":"20e441",
"class":"cell txt l",
"children":[
"Decrease in CVD events and kidney failure in individuals with type 2 diabetes and kidney disease with canagliflozin (CREDENCE)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"l"
]
}
]
},
" ",
{
"type":"p",
"hlId":"ccef54",
"class":"cell txt l",
"children":[
"Decreased risk of hospitalization for heart failure in patients with type 2 diabetes and established CVD with dapagliflozin (DECLARE-TIMI 58)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"m"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd1d2d",
"class":"cell txt l",
"children":[
"Bile acid sequestrants (colesevelam)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a1473",
"class":"cell txt l",
"children":[
"Incompletely understood:"
]
},
" ",
{
"type":"p",
"hlId":"26a808",
"class":"cell txt l",
"children":[
"Possible decrease in hepatic glucose production"
]
},
" ",
{
"type":"p",
"hlId":"43501d",
"class":"cell txt l",
"children":[
"Possible increase in incretin levels"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9d6f5",
"class":"cell txt l",
"children":[
"Constipation, dyspepsia, increased triglycerides, possible interference with absorption of other medications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"65e3a7",
"class":"cell txt l",
"children":[
"Dopamine-2 agonists (bromocriptine quick release)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5113bd",
"class":"cell txt l",
"children":[
"Increases insulin sensitivity"
]
},
" ",
{
"type":"p",
"hlId":"55ff47",
"class":"cell txt l",
"children":[
"Alters metabolism via hypothalamus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b33100",
"class":"cell txt l",
"children":[
"Nausea, orthostasis, fatigue"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb112c",
"class":"cell txt l",
"children":[
"Possible decrease in CVD events (Cycloset Safety Trial)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"n"
]
}
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CV = cardiovascular; CVD = cardiovascular disease; DKA = diabetic ketoacidosis; DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; MI = myocardial infarction; SGLT2 = sodium-glucose cotransporter 2."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Data from American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S111-S124. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298420",
"target":"_blank"
},
"children":[
"PMID: 33298420"
]
},
" doi:10.2337/dc21-S009"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Data from Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al; American Association of Clinical Endocrinologists (AACE). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract. 2018;24:91-120. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29368965",
"target":"_blank"
},
"children":[
"PMID: 29368965"
]
},
" doi:10.4158/CS-2017-0153"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Data from Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/9742976",
"target":"_blank"
},
"children":[
"PMID: 9742976"
]
}
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Data from Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-65. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/9742977",
"target":"_blank"
},
"children":[
"PMID: 9742977"
]
}
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"Data from Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-94. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/12876091",
"target":"_blank"
},
"children":[
"PMID: 12876091"
]
}
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
},
"Data from Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/16214598",
"target":"_blank"
},
"children":[
"PMID: 16214598"
]
},
" doi:10.1016/S0140-6736(05)67528-9"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"g"
]
},
"Data from Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/23992601",
"target":"_blank"
},
"children":[
"PMID: 23992601"
]
},
" doi:10.1056/NEJMoa1307684"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"h"
]
},
"Data from Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311-22. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27295427",
"target":"_blank"
},
"children":[
"PMID: 27295427"
]
},
" doi:10.1056/NEJMoa1603827"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"i"
]
},
"Data from Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27633186",
"target":"_blank"
},
"children":[
"PMID: 27633186"
]
},
" doi:10.1056/NEJMoa1607141"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"j"
]
},
"Data from Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117-28. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26378978",
"target":"_blank"
},
"children":[
"PMID: 26378978"
]
},
" doi:10.1056/NEJMoa1504720"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"k"
]
},
"Data from Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377:644-657. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28605608",
"target":"_blank"
},
"children":[
"PMID: 28605608"
]
},
" doi:10.1056/NEJMoa1611925"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"l"
]
},
"Data from Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380:2295-2306. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30990260",
"target":"_blank"
},
"children":[
"PMID: 30990260"
]
},
" doi:10.1056/NEJMoa1811744"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"m"
]
},
"Data from Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018;200:83-89. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29898853",
"target":"_blank"
},
"children":[
"PMID: 29898853"
]
},
" doi:10.1016/j.ahj.2018.01.012"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"n"
]
},
"Data from Gaziano JM, Cincotta AH, O’Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33:1503-8. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/20332352",
"target":"_blank"
},
"children":[
"PMID: 20332352"
]
},
" doi:10.2337/dc09-2009"
]
]
}